Moreover, the lentivirus-based chimeric antigen receptor-modified T (CAR-T) cells targeting CD19 therapy was evaluated in 30 children and adults with relapsed acute lymphoblastic leukemia (ALL) [128]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.